Sugi Predict

Sugi Predict / Compounds / SCHEMBL5432248

SCHEMBL5432248

SCHEMBL5432248

N=C(N)NC(=O)/C=C/c1ccc(C(F)(F)F)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC3 O15379 1/20 0.67
▸ ADAM17 P78536 1/20 0.67
▸ HDAC1 Q13547 1/20 0.67
▸ HDAC2 Q92769 1/20 0.67
▸ HDAC10 Q969S8 1/20 0.67
▸ HDAC11 Q96DB2 1/20 0.67
▸ HDAC8 Q9BY41 1/20 0.67
▸ HDAC6 Q9UBN7 1/20 0.67
▸ HDAC5 Q9UQL6 1/20 0.67
▸ MAOB P27338 4/20 0.59
▸ CYP1A2 P05177 1/20 0.58
▸ CA12 O43570 1/20 0.53
▸ CA1 P00915 1/20 0.53
▸ CA2 P00918 1/20 0.53
▸ CA9 Q16790 1/20 0.53
▸ CYP1A1 P04798 3/20 0.52
▸ CYP1B1 Q16678 3/20 0.52
▸ TRPA1 O75762 1/20 0.51
▸ TRPM8 Q7Z2W7 1/20 0.51
▸ NOS3 P29474 3/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5432252 1.00 HDAC3 (0.67) HDAC3ADAM17HDAC1HDAC2HDAC10
SCHEMBL5433870 0.85 CYP1A2 (0.58) HDAC1HDAC8CYP1A2
SCHEMBL5433876 0.85 CYP1A2 (0.58) HDAC1HDAC8CYP1A2
SCHEMBL5443370 0.84 LMNA (0.56) MAOBCA12CA1CA2CA9
SCHEMBL5443373 0.84 LMNA (0.56) MAOBCA12CA1CA2CA9
SCHEMBL5443382 0.83 MEN1 (0.64) MAOBCA12CA1CA2CA9
SCHEMBL5443384 0.83 MEN1 (0.64) MAOBCA12CA1CA2CA9
SCHEMBL5432579 0.81 MAOB (0.59) HDAC3HDAC1HDAC2HDAC10HDAC11
SCHEMBL27815019 0.81 HDAC3 (0.75) HDAC3ADAM17HDAC1HDAC2HDAC10
SCHEMBL5432574 0.81 MAOB (0.59) HDAC3HDAC1HDAC2HDAC10HDAC11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2617709-B1 Guanidine derivatives as antiviral agents BIOTRON LTD (AU) 2022-11-16 — — EP claimed
US-10472332-B2 Antiviral compounds and methods BIOTRON LIMITED (AU) 2019-11-12 — — US claimed
US-20170260147-A1 ANTIVIRAL COMPOUNDS AND METHODS BIOTRON LIMITED (AU) 2017-09-14 — — US claimed
US-20150313909-A1 ANTIVIRAL COMPOUNDS AND METHODS BIOTRON LIMITED (AU) 2015-11-05 — — US claimed
EP-2617709-A1 Guanidine derivatives as antiviral agents Biotron Limited (AU) 2013-07-24 — — EP claimed
US-20130035328-A1 ANTIVIRAL COMPOUNDS AND METHODS GAGE PETER WILLIAM (AU) 2013-02-07 — — US claimed
US-20070099968-A1 Antiviral compounds and methods BIOTRON LIMITED (AU) 2007-05-03 — — US claimed
EP-1646371-A2 ANTIVIRAL COMPOUNDS AND METHODS Biotron Limited (AU) 2006-04-19 — — EP claimed
WO-2004112687-A2 ANTIVIRAL ACYLGUANIDINE COMPOUNDS AND METHODS BIOTRON LIMITED (AU) 2004-12-29 — — WO claimed
EP-2617709-B1 Guanidine derivatives as antiviral agents BIOTRON LTD (AU) 2022-11-16 — — EP disclosed
US-11192863-B2 Antiviral compounds and methods BIOTRON LIMITED (AU) 2021-12-07 — — US disclosed
US-11192863-B2 Antiviral compounds and methods BIOTRON LIMITED (AU) 2021-12-07 — — US disclosed
US-10472332-B2 Antiviral compounds and methods BIOTRON LIMITED (AU) 2019-11-12 — — US disclosed
US-10472332-B2 Antiviral compounds and methods BIOTRON LIMITED (AU) 2019-11-12 — — US disclosed
EP-2617709-A1 Guanidine derivatives as antiviral agents Biotron Limited (AU) 2013-07-24 — — EP disclosed
US-20130035328-A1 ANTIVIRAL COMPOUNDS AND METHODS GAGE PETER WILLIAM (AU) 2013-02-07 — — US disclosed
US-20130035328-A1 ANTIVIRAL COMPOUNDS AND METHODS GAGE PETER WILLIAM (AU) 2013-02-07 — — US disclosed
US-20070099968-A1 Antiviral compounds and methods BIOTRON LIMITED (AU) 2007-05-03 — — US disclosed
US-20070099968-A1 Antiviral compounds and methods BIOTRON LIMITED (AU) 2007-05-03 — — US disclosed
US-20070099968-A1 Antiviral compounds and methods BIOTRON LIMITED (AU) 2007-05-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11192863-B2 Antiviral compounds and methods MAVS, ZC3HAV1, EIF2AK2 HDAC3 262/4885ADAM17 1253/4885HDAC1 336/4885
US-10472332-B2 Antiviral compounds and methods MAVS, ZC3HAV1, EIF2AK2 HDAC3 262/4885ADAM17 1253/4885HDAC1 336/4885
US-20070099968-A1 Antiviral compounds and methods MAVS, ZC3HAV1, EIF2AK2 HDAC3 409/4885ADAM17 650/4885HDAC1 400/4885
US-20170260147-A1 ANTIVIRAL COMPOUNDS AND METHODS MAVS, ZC3HAV1, EIF2AK2 HDAC3 262/4885ADAM17 1253/4885HDAC1 336/4885
US-20130035328-A1 ANTIVIRAL COMPOUNDS AND METHODS ZC3HAV1, MAVS, EIF2AK2 HDAC3 293/4885ADAM17 779/4885HDAC1 269/4885
US-20150313909-A1 ANTIVIRAL COMPOUNDS AND METHODS ZC3HAV1, MAVS, EIF2AK2 HDAC3 293/4885ADAM17 779/4885HDAC1 269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.